<unk>  technical name CIGB-66, is a COVID-19 vaccine developed by the Center for Genetic Engineering and Biotechnology in Cuba. This candidate, named after a patriotic drama by Cuban independence hero José Martí, is a protein subunit vaccine containing COVID-derived proteins that trigger an immune response. The full results of the clinical trial have not yet been published. This candidate followed a previous one called CIGB-669 (MAMBISA). The vaccine is one of two Cuba-developed COVID-19 vaccines which has passed Phase III trials, and has received emergency authorisation.
Abdala 
Tabun 
Kuru 
Kuru
Samu
Kava
WebTeb
Koro 